Core Viewpoint - Jiahe Meikang (688246.SH) is currently trading at 24.86 yuan, reflecting a decline of 2.09% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Jiahe Meikang was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 14, 2021, with an initial offering price of 39.50 yuan per share [1] - The company issued a total of 34.4694 million shares during its IPO, raising a total of 1.362 billion yuan, with a net amount of 1.240 billion yuan after deducting issuance costs [1] - The final net fundraising amount exceeded the original plan by 490 million yuan [1] Group 2: Fundraising and Use of Proceeds - The company initially planned to raise 750 million yuan, which was allocated for the development of specialized electronic medical records (in emergency and maternal-child health), upgrading of comprehensive electronic medical records, data center upgrades, and to supplement working capital [1] - The total issuance costs for the IPO amounted to 121 million yuan, with the lead underwriter, Huatai United Securities Co., Ltd., receiving 97.823 million yuan in underwriting fees [1]

Core Viewpoint - Jiahe Meikang (688246.SH) announced a share reduction plan by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center, indicating a decrease in shareholding from 12.6845 million shares to 12.2576 million shares, representing a reduction from 9.22% to 8.91% of the total share capital [1] Summary by Relevant Sections - Share Reduction Details - On October 20, 2025, Guoshou Chengda reduced its holdings by 426,900 shares through centralized bidding [1] - The reduction has not yet been fully implemented [1] - Current Shareholding Status - After the reduction, Guoshou Chengda holds 12.2576 million shares, which is 8.91% of the total share capital [1]

一、信息披露义务人及其一致行动人的基本信息 1.身份类别 | | | 重要内容提示： 权益变动方向 比例增加□ 比例减少 权益变动前合计比例 9.22% 权益变动后合计比例 8.91% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否 是否触发强制要约收购义务 是□ 否 投资者及其一致行动人的身份 □控股股东/实际控制人及其一致行动人 其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他______________（请注明） 2.信息披露义务人信息 证券代码：688246 证券简称：嘉和美康 公告编号：2025-064 嘉和美康（北京）科技股份有限公司 关于持股 5%以上股东权益变动触及 1%刻度的提示性 公告 股东国寿成达（上海）健康产业股权投资中心（有限合伙）保证向本 公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 | 投资者名称 | 变动前股数 | 变动前比例 | 变动后股数 | 变动后比例 | 权益变动方 | 权益变动的 | | --- | - ...

Core Viewpoint - Jiahe Meikang clarified that it does not directly manage customer data but is entrusted to govern and apply customer data under compliance [1] Group 1: Data Governance and Application - The company has various business lines involved in data governance and application [1] - The medical data business department has a significant number of personnel involved, with over 200 expected by the end of 2024 [1]

Core Viewpoint - The company Jiahe Meikang (688246.SH) clarified on its investor interaction platform that it is not involved in the brain-computer interface field [1] Company Summary - Jiahe Meikang has explicitly stated its non-involvement in the brain-computer interface sector, indicating a clear focus on its current business operations [1]

Core Viewpoint - The U.S. government, led by President Trump, announced a 100% tariff on all Chinese goods starting November 1, along with export controls on key software, which will accelerate the domestic software replacement process in China [2][3]. Group 1: U.S. Trade Measures - The U.S. will impose a 100% additional tariff on all Chinese imports and export controls on key software starting November 1 [2]. - The U.S. measures are seen as a strategic move to pressure China ahead of the APEC summit, with potential implications for negotiations [2][3]. Group 2: China's Response and Industry Impact - China's Ministry of Commerce has implemented export controls on various technologies, including chip production equipment and lithium batteries, which are crucial for modern industries [2][3]. - China is expected to dominate the rare earth industry by 2025, holding 49% of global reserves and 69% of production, making it a critical resource for the U.S. [2][3]. Group 3: Domestic Software Development - The export controls on key software will accelerate the domestic replacement process in China, particularly in the fields of EDA, CAD, CAE, MES, and PLM [3][4]. - The shift towards domestic software is seen as essential due to China's heavy reliance on imported industrial software [3][4]. Group 4: Industrial Digital Transformation - The announcement of using WPS format in government documents marks a significant milestone for domestic software, indicating a breakthrough in the software replacement strategy [4]. - "Lighthouse factories," which utilize advanced technologies for efficiency, are expected to be prioritized in national strategic development plans, driving demand for industrial software [4]. Group 5: Investment Opportunities - Companies in the EDA, industrial software, operating systems, databases, network security, and industry IT sectors are highlighted as potential investment opportunities due to the ongoing shift towards domestic solutions [4]. - Specific companies to watch include: - EDA: Huada Jiutian, Guangliwei, Gai Lun Electronics [4] - Industrial Software: Dingjie Zhizhi, Nengke Technology, Suochen Technology, Zhongwang Software, Zhongkong Technology [4] - Operating Systems: China Software, Ruantong Power, Runhe Software, Chengmai Technology [4] - Databases: Dameng Data, Taiji Co. [4] - Network Security: Deepin Technology, Qilin Security, Sanwei Security, Guotou Intelligent, Qimingxing Chen [4] - Industry IT: Keda Xunfei, Hehe Information, Hengsheng Electronics, Kingsoft Office, Foxit Software, Tuolisi, Tax Friend Shares, Caixun Shares, Dingdian Software, Jiuyuan Yinhai, Jiahe Meikang, Guanglian Da, Kingdee International, Yonyou Network, Fanwei Network, Yuxin Technology, Newland [4].

Investment Rating - The report maintains a positive outlook for the computer industry, expecting a continued "scissor difference" in Q3 2025, indicating structural growth despite varying performance among companies [3][4][11]. Core Insights - The report predicts that 22% of the tracked companies will see net profit growth exceeding 50%, with notable performers including 深信服 (1528%), 卡莱特 (998%), and 新国都 (235%) [4][5]. - The report highlights a trend of cost reduction through layoffs and non-essential cost cuts, leading to improved efficiency and profitability across the industry [3][4]. - The report identifies key investment targets in various segments, including AIGC, digital economy leaders, and data innovation [3][4]. Summary by Sections Q3 2025 Performance Forecast - Among 54 tracked companies, 11 are expected to exceed 50% profit growth, while 9 will see growth between 30%-50% [4][5]. - 36% of companies are projected to have growth between 0%-30%, and 22% are expected to experience a decline [5][6]. Key Company Performances - 深信服 is projected to achieve a staggering 1528% profit growth, while 卡莱特 is expected to see 998% growth [4][5]. - Companies like 海康威视 and 金山办公 are expected to maintain stable growth rates of around 9% and 15%, respectively [8][10]. - 联想集团 is forecasted to face a significant decline of 99% in profit, indicating challenges in its operational strategy [6][10]. Investment Targets - The report categorizes investment targets into four segments: AIGC, digital economy leaders, data innovation, and AIGC computing power [3][4]. - Notable companies in the AIGC segment include 金山办公 and 道通科技, while 海光信息 and 软通动力 are highlighted in the data innovation category [3][4].

Core Viewpoint - 嘉和美康's financial performance in the first half of 2025 shows significant declines in revenue and net profit, indicating ongoing challenges for the company [1][2]. Financial Performance Summary - In the first half of 2025, 嘉和美康 reported revenue of 2.19 billion yuan, a decrease of 27.22% year-on-year [1][2]. - The net profit attributable to shareholders was -1.16 billion yuan, and the net profit after deducting non-recurring gains and losses was -1.18 billion yuan [1][2]. - The net cash flow from operating activities was -1.68 billion yuan [1][2]. Previous Year Comparison - For the year 2024, 嘉和美康 achieved revenue of 5.92 billion yuan, down 14.85% from 2023 [3]. - The net profit attributable to shareholders for 2024 was -2.56 billion yuan, compared to a profit of 32.28 million yuan in the previous year [3]. - The net cash flow from operating activities for 2024 was -67.63 million yuan [3]. IPO and Fundraising - 嘉和美康 raised a total of 1.362 billion yuan from its initial public offering, with a net amount of 1.24 billion yuan after deducting issuance costs [4]. - The company initially planned to raise 750 million yuan for various projects, including electronic medical record development and data center upgrades [4].

Core Insights - The medical information technology industry is undergoing significant consolidation, with major acquisitions signaling a shift in the market dynamics after a period of rapid growth [1][2][3] - The demand for medical IT solutions has decreased as most hospitals have met previous regulatory requirements, leading to a more cautious approach in project approvals and increased competition among firms [3][4][6] - The integration of AI and new technologies is expected to drive the next phase of growth in the medical IT sector, creating opportunities for companies that can adapt to changing market needs [9] Industry Trends - Recent acquisitions include the purchase of medical consulting firm Yice Medical Management by Xisoft Technology, indicating a trend where larger firms seek to enhance their service offerings by integrating complementary smaller companies [1][7] - The medical IT industry experienced a boom from 2018 to mid-2023, driven by regulatory support and technological advancements, but has since faced challenges due to market saturation and budget constraints in hospitals [2][3][8] - The push for digital transformation in hospitals has led to a demand for more comprehensive solutions that integrate various operational aspects, moving beyond simple IT services [4][6] Market Dynamics - The competitive landscape is shifting as smaller firms struggle to meet the new demands for standardized solutions, while larger firms are better positioned to capitalize on these changes through strategic acquisitions [6][8] - The focus on cost control and efficiency in hospitals has made it more challenging for medical IT companies to secure contracts, as decision-makers are now more cautious and selective [3][6] - The ongoing consolidation in the industry is expected to enhance the bargaining power of remaining firms and may lead to a more concentrated market structure [8][9]

Group 1 - On September 25, Jiahe Meikang's stock rose by 3.20%, with a trading volume of 93.32 million yuan [1] - The financing buy-in amount for Jiahe Meikang on that day was 22.23 million yuan, while the financing repayment was 11.74 million yuan, resulting in a net financing buy-in of 10.50 million yuan [1] - As of September 25, the total balance of margin trading for Jiahe Meikang was 193 million yuan, accounting for 4.73% of its market capitalization [1] Group 2 - As of June 30, the number of shareholders for Jiahe Meikang was 6,655, an increase of 12.93% compared to the previous period [2] - For the first half of 2025, Jiahe Meikang reported operating revenue of 219 million yuan, a year-on-year decrease of 27.22% [2] - The net profit attributable to the parent company for the same period was -116 million yuan, representing a year-on-year decrease of 323.29% [2] Group 3 - The main business of Jiahe Meikang includes medical information software development and industrialization, with revenue composition as follows: software development and technical services 42.39%, self-developed software sales 37.64%, purchased software and hardware sales 19.86%, and other service sales 0.11% [1]